Appendix



Figure 1 – The renin-angiotensin-aldosterone system and kinin-kallikrein system. ACE-inhibitors (ACEI) slow the degradation of bradykinin leading to increased bradykinin β2 receptor activation and increased vascular permeability (1-3). Candidate treatments for ACEI angioedema are highlighted in red.

ACE – angiotensin converting enzyme; ACEi – ACE-inhibitor; FFP – fresh frozen plasma; HMW – high molecular weight; DPP4 – dipeptidyl peptidase-4; ARB – angiotensin II receptor blocker.

1. Craig TJ, Bernstein JA, Farkas H, Bouillet L, Boccon-Gibod I. Diagnosis and treatment of bradykinin-mediated angioedema: outcomes from an angioedema expert consensus meeting. Int Arch Allergy Immunol. 2014;165(2):119-27.
2. Byrd JB, Woodard-Grice A, Stone E, Lucisano A, Schaefer H, Yu C, et al. Association of angiotensin-converting enzyme inhibitor-associated angioedema with transplant and immunosuppressant use. Allergy. 2010;65(11):1381-7.
3. Campbell DJ. Neprilysin Inhibitors and Bradykinin. Front Med (Lausanne). 2018;5:257.